Valeo Pharma Inc. · OTC:VPHIF
Valeo Pharma — Investor Presentation (March 2023)
28 slides from Valeo Pharma's investor presentation, March 2023
Slide 1: Corporate Presentation March 2023
Valeo Stands for Innovation, Innovation Sparks Life Corporate Presentation March 2023 (TSX: VPH) (OTCQB: VPHIF)
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Forward-Looking Statements: This presentation, including the documents incorporated by reference herein, contains “forward-looking information” as defined under Canadian securities laws (collectively, “forward-looking statements”). All statements other than statements of h
Slide 3: Who We Are
WHO WE ARE Overview - Founded in 2003 - Fully integrated pharmaceutical company - Dedicated to commercialization of prescription products in Canada - Licenses / acquires Canadian rights to commercial stage drugs - Pure commercial play, No R&D or manufacturing PAGE 3 - Industry leading growth rate -
Slide 4: Revenues: Historical & Forecasted
Revenues: Historical & Forecasted EXISTING AND OFRECASTED REVENUES Revenues $ Millions 120 100 100 80 PAGE 4 63 60 40 27.7 20 13.6 6.6 7.5 0 2019 2020 2021 2022 2023 F 2024F TSX:VPH
Slide 5: Business Units
3 Business Units Ophthalmology BUSINESS UNITS Respiratory / Allergy Respiratory Allergy XIIDRA® SIMBRINZA® ENERZAIR® ALLERJECT® PAGE 5 ATECTURA® Specialty Products 8 Spec. Products Neurology Oncology REDESCA® ONSTRYV® YONDELIS® TSX:VPH M-ESLON® SABIZABULIN
Slide 6: 2021-2022 Transformative Product Additions
2021-2022 Transformative Product Additions TRANSFORMATIVE LAUNCHES Revenues 160 Q4-21 Launch: ENERZAIR® Q4-22 Launch: XIIDRA® 140 ATECTURA® SIMBRINZA® 120 ALLERJECT® Q3-21 Launch: REDESCA® 100 Millions 80 PAGE 6 60 40 20 0 FY-20 A FY-21 A FY-22 A FY-23 F FY-24 F FY-25 F Ophthalmology Respiratory / A
Slide 7: Product Portfolio
PRODUCT PORTFOLIO FAST Growing Commercial Products Portfolio Launched Est. Peak Sales Est. 2023 RESPIRATORY / ALLERGY /Acquired ($M) Revenues ENERZAIR® Asthma 2021 $90 + ATECTURA® Asthma 2021 $30 + $16M ALLERJECT® Allergy 2022 $25 + Total $145 OPHTHALMOLOGY XIIDRA® Dry eye disease 2022 $30 + $63M PA
Slide 8: Respiratory / Allergy Business Unit
Respiratory / Allergy Business Unit Launched Est. Peak Sales Est. 2023 RESPIRATORY / ALLERGY /Acquired ($M) Revenues ENERZAIR® Asthma 2021 $90 + ATECTURA® Asthma 2021 $30 + $16M ALLERJECT® Allergy 2022 $25 + Total $145
Slide 9: Asthma: Canadian Market Dynamics
ASTHMA: CANADIAN DYNAMICS Asthma: Canadian Market Dynamics ➢ Canadian asthma sufferers: 3.8 M ➢ Targeted Patient Population: 1.0 M ➢ % of asthma sufferers with uncontrolled symptoms: 50% + ➢ Canadians under chronic treatment: 1.4 M Triple Therapy : Fastest growing ➢ E.R. Visits (2015) from severe as
Slide 10: Enerzair & Atectura Breezhaler
ENERZAIR / ATECTURA PAGE 10 ENERZAIR & ATECTURA BREEZHALER Enerzair Atectura Launched Q4-21, Q4-21, First in Class Best in Class Target Market 350k Patients 615K Patients Triple Agent Therapy Peak Sales $90M $30M % of Patients @ Peak 43% 14 % Share of New 69% 7% Prescriptions Partner Novartis Canada
Slide 11: Enerzair / Atectura Clinical Results
CLINICAL RESULTS ENERZAIR ® / ATECTURA® Clinical Results First in class Best in class triple combination Dual combination ICS/LABA/LAMA LABA/ICS ENERZAIR ENERZAIR ATECTURA vs Vs vs ADVAIR LOOSE TRIPLE Rate ratio (95% Cl) ADVAIR Rate ratio (95% Cl) 1.0 - 0.78 (0.66, 0.93) 0.74 (0.61, 0.91) 0.9 - +96m
Slide 12: Prescription Trends
PRESCRIPTION TRENDS Prescription Trends # of Prescribers TRx - MAT 1,583 1,600 35,000 33,920 32,899 1,429 1,400 420 1,284 30,000 28,253 1,200 1,136 394 25,000 24,024 1,004 370 17,691 18,705 1,000 20,201 883 342 20,000 15,199 779 313 16,875 800 PAGE 12 683 12,948 283 259 15,000 13,669 558 10,902 600
Slide 13: Allerject
ALLERJECT® ALLERJECT Licensed: Q3-2022 Partner Kaléo, Inc. (US) Target market: 1M units / YR Market Size: $80M + / CAGR 5-8% PAGE 13 Peak Sales: $25M / 30% market share Calendar 2021 sales: $4M / ~5% market share IMPORTANT : Allerject had 36% market share before re-engineering Product re-launched in
Slide 14: Allerject Advantages
ALLERJECT ADVANTAGES Competitive Advantages vs Market Leader Features Epipen Allerject (Market leader) Annual Revenues $75-80M $4-5M Pricing $95-105 Same Reimbursement 75% coverage Same Voice activated No Yes FDA Guidance for Device Reliability N.A. First to meet 99.999% PAGE 14 User Friendly Averag
Slide 15: Ophthalmology Business Unit
Ophthalmology Business Unit Launched Est. Peak Sales Est. 2023 OPHTHALMOLOGY /Acquired ($M) Revenues XIIDRA® Dry eye disease 2022 $30M + $25M SIMBRINZA® Glaucoma 2022 $15M + Total $45M
Slide 16: Xiidra: Dry Eye Disease
XIIDRA XIIDRA®: Dry Eye Disease Licensed : Q3-2022 Partner: Novartis Target Market: 8M people, 2% treated with RX PAGE 16 1,200 Ophthalmologists Current Market Share: 31% 2021 Sales: $15M Peak Sales: $30M + Market CAGR: 5-6% TSX:VPH
Slide 17: Simbrinza: Glaucoma
SIMBRINZA®: Glaucoma SIMBRINZA Licensed: Q3-2022 Partner: Novartis Target Market: 400,000 Canadians PAGE 17 1,200 Ophthalmologists 2021 Sales: $8M Current Market Share: 18% Peak Sales: $15M + Market CAGR: 4-5% TSX:VPH
Slide 18: Xiidra & Simbrinza Revenues
XIIDRA & SIMBRINZA REVENUES XIIDRA® – SIMBRINZA® Revenues Valeo acquires PEAK SALES 50,000,000 commercial rights >$40m (July 22) 40,000,000 XIIDRA Net TO SIMBRINZA Net TO 30,000,000 PAGE 18 20,000,000 10,000,000 0 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Xiidra: “Unpromoted” since 2021
Slide 19: Specialty Products Business Unit
Specialty Products Business Unit SPECIALTY PRODUCTS Launch Est. Peak Sales Est. 2023 / Acquired (M) Revenues REDESCA® Blood Thinner 2021 $25 + M-ESLON® Pain (Tablet) 2016 $10 $22M Others Parkinson/Oncology 2020 $5 + Total $40
Slide 20: Redesca (Biosimilar)
Redesca® (Biosimilar) REDESCA Launch: Q2-2021 Target market: $180M Peak sales: $25M Partner: Shenzhen Techdow Pharmaceuticals, PAGE 20 (World largest Heparin manufacturer) Phase 1 Phase 2 Phase 3 2021-22 2022-23 2022-26 Primary Market – Rest of Canada Secondary Early Adopter (Ont, Maritimes, Market
Slide 21: LMWH Biosimilar Market
LMWH Biosimilar Market insight:Jan.-23 Monthly - IQVIA BIOSIMILAR MARKET 100% 100% 90% 90% 80% 80% 70% 70% 61 60% % 60% 50% 50% PAGE 21 40% 40% 30% 30% 20% 20% 10% 10% 0% Feb-21 Sep-21 Feb-22 Sep-22 Dec-21 Dec-22 Jun-21 Aug-21 Jan-22 Jun-22 Aug-22 Jan-23 Apr-21 Jul-21 Mar-21 Oct-21 Apr-22 Jul-22 Nov
Slide 22: Financials and Summary
Financials and Summary
Slide 23: Sequential P&L Improvement
Sequential P&L Improvement P&L IMPROVEMENTS 16 • Q1-23: 14 • 5th consecutive Q of revenue growth up 210% over Q1-22 12 • 5th consecutive Q of adjusted gross profit increase up 178% over Q1-22 10 • 5th consecutive Q of adjusted EBITDA loss reduction 51% better Q1-22 • 2023 Current Revenues run rate:
Slide 24: New Products to Fuel Growth for Many Years
YEARS OF GROWTH New Products to fuel growth for many years Revenues (millions $) ▪ New products to help 160 DOUBLE Valeo’s revenues 140 ▪ 6 major brands to drive Xiidra Simbrinza top line and margin 120 Allerject expansion for 5+ years 100 Q4-22 PAGE 24 ▪ Peaks Sales now Exceeds 80 Redesca launch in
Slide 25: Leadership
LEADERSHIP TEAM Leadership MANAGEMENT BOARD Steve Saviuk Richard J. MacKay Maureen C. Brennan Founder, CEO Chairman Board Member Founder and CEO Since 2003 Former Vice-Chairman 40+ years in private and of Stiefel Laboratories public health sector Former Director General Luc Mainville Steve Saviuk Sh
Slide 26: Capital Structure
Capital Structure, as at March. 16, 2023 CAPITAL STRUCTURE CAPITALIZATION MILLIONS Shares Outstanding (Share Price - $0.53) 83.9 Options/RSUs (avg. price, $0.64) 6.1 Warrants (avg. strike price $1.02) 15.6 Convertible debentures ($25.7M) 21.9 Management & Insiders PAGE 26 aligned with Fully-Diluted
Slide 27: Investment Thesis
INVESTMENT THESIS Investment Thesis - Industry leading topline growth 2023 and beyond - Pure commercial play, NO R&D / manufacturing - 12 commercialized products - 6 growth assets launched/acquired last 2 yrs. PAGE 27 - Significant growth of peak sales potential(≥ $230M) - Significant operating leve
Slide 28: Contact Us
Contact Us PHONE 514-694-0150 EMAIL ir@valeopharma.com WEB www.valeopharma.com